SABCS 2022
Camizestrant Improves PFS vs Fulvestrant in ER+/HER2- Advanced Breast Cancer
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
Your search for esrd returned 10 results
SABCS 2022
Duration of Prior CDK4/6 Inhibitor Treatment Tied to PFS With Elacestrant
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
News
Erectile Dysfunction Meds Tied to Higher Risk for Vision Issues
Regular users may be at risk for serous retinal detachment, retinal vascular occlusion, and ischemic optic neuropathy
News
Comparable Adverse Effects Seen for HIF-PHIs and ESAs
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.
News
Uric Acid-Lowering Therapy May Increase Risk for CKD
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
News
Nonsteroidal MRAs Reduce Kidney, Cardiovascular Risks
The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease.
News
Preferential Use of Lactated Ringer vs Saline May Reduce Adverse Kidney Events
This study raises important questions about the choice between lactated Ringer and saline.
News
Diuretic Use Varies Widely in US Hemodialysis Practice
Uncertainty regarding diuretic efficacy and optimal dosing in hemodialysis likely contributes to practice variation, according to investigators.
News
SGLT2 Inhibitors Underprescribed for Chronic Kidney Disease
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
News
Underuse of Diabetic Kidney Disease Therapies Reported
Study findings highlight an "unmet need" for newer therapies.
